Fourth Quarter Highlights
Per Class B share(3): $1.03 adjusted basic earnings up 1.0%; $0.99 basic earnings down 2.0%; currency translation positive $0.04 per share
Sales increased 3.5% on 0.6% organic growth, 0.2% acquisition growth and 2.7% positive currency translation
CCL Segment and Avery posted organic sales growth of 3.6% and 3.8%, respectively, partly offset by organic declines for Checkpoint and Innovia of 8.1% and 9.1%, respectively
Operating income(1) improved 4.8%, with a 15.0% operating margin(1) up 20 bps
2025 Highlights
Per Class B share(3): $4.64 adjusted basic earnings up 7.4%; $4.59 basic earnings down 3.0%; $0.44 revaluation gain included in 2024 basic earnings; currency translation positive $0.10 per share on an adjusted basis
Sales increased 5.8% on 2.5% organic growth, 0.7% acquisition growth and 2.6% positive currency translation
Operating income(1) improved 8.7%, with a 16.2% operating margin(1) up 40 bps
Returned $523.7 million to shareholders: $223.7 million in dividends and repurchased 3.9 million Class B shares for $300.0 million.
(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.)
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year
Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2
U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with potential launch this year
PN-881 Phase 1 completion expected by mid-2026
Pre-clinical pipeline expanded with novel wholly-owned candidates PN-477, an oral and s.c. triple GLP-GIP-GCG agonist and PN-458, an oral and s.c. dual GLP-GIP agonist, and PN-8047, an oral hepcidin functional mimetic
Cash, cash equivalents and marketable securities of $646 million as of December 31, 2025, anticipated to provide cash runway through at least end of 2028
Read More
NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year
Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2
U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with
potential launch this year
PN-881 Phase 1 completion expected by mid-2026
Read More
The National Children's Cancer Society (NCCS) is proud to announce it has earned the Platinum Seal of Transparency from Candid, the highest level of recognition awarded to nonprofit organizations for openness and accountability.
Read More
Sony IMX900 Pregius S Industrial Global Shutter UVC Camera | Ultra Fast 20Gbps USB 3.2 Gen 2x2 | Quad HDR and Quad Shutter Control | Excellent NIR Sensitivity at 850nm and 940nm
Read More
Backed by Spark Capital, Kleiner Perkins, and Cyberstarts, Gambit Security is the first AI-native resilience platform trusted by enterprises to deliver verifiable, continuous resilience, exposing hidden risks before they become catastrophic downtime. Through recent research, Gambit uncovered how a single AI-directed attacker compromised nine Mexican government institutions and exposed 195 million identities.
Read More
Navigating Contrasting Messaging by legacy media from Disney (DIS), Paramount Global (PARA), Comcast (CMCSA), Warner Bros. Discovery (WBD), and Newsmax (NMAX), Sinclair (SBGI), and Fox Corp. (FOX), Patriot.TV Provides Accurate Narrative regarding Elections.
Read More
BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.
Read MoreCeramics and High-Temperature Processing Expert Dr. William M. Carty, Ph.D., Engaged to Lead Ferroboron Trial
Targets Supplying Magnet-Grade Ferroboron to Potential Customers for Initial Qualification in First Half of 2026
Read MoreThis press release is issued pursuant to Multilateral Instrument 62-104 - Take-Over Bids and Issuer Bids and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issuers ("NI 62-103").
Read MoreDelivery Marks Advancement of Collaborative Deployment Efforts as Due Diligence Continues and Infrastructure Planning Progresses
Read More
Founder Julie Brangstrup Hosts Miami Press Conference to Announce 4-Day Tour, Uniting International Women Leaders in Luxury, Culture, and Philanthropy Across Charleston, Jacksonville, Palm Beach, and Miami
Read More